These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38738340)

  • 1. Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
    Hu S; Shi C; Ma Y; Wang S; Gu S; Qi C; Fan G
    Diabetes Obes Metab; 2024 Aug; 26(8):3176-3190. PubMed ID: 38738340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
    Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
    J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
    Hu S; Gu S; Qi C; Wang S; Qian F; Shi C; Fan G
    Diabetes Obes Metab; 2023 Feb; 25(2):387-397. PubMed ID: 36193880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
    Hu S; Wang S; Qi C; Gu S; Shi C; Mao L; Fan G
    Front Pharmacol; 2022; 13():831364. PubMed ID: 35250578
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
    Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
    Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Karagiannis T; Malandris K; Avgerinos I; Stamati A; Kakotrichi P; Liakos A; Vasilakou D; Kakaletsis N; Tsapas A; Bekiari E
    Diabetologia; 2024 Jul; 67(7):1206-1222. PubMed ID: 38613667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 14. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
    Zhang X; McAdam Marx C
    J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.
    Al-Omar HA; Almodaimegh HS; Omaer A; Alzubaidi LM; Al-Harbi B; Al-Harbi I; Hassan M; Akhtar O
    J Med Econ; 2024; 27(1):418-429. PubMed ID: 38420695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
    Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
    Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.